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We investigated the effects of CGRP on glucose metabolism in intact rat skeletal muscle preparations that are largely 
composed ofeither type I (soleus) or II fibres (e.g. extensor digltorum longus (EDL) or epitrochlearis muscles). CGRP-1 
inhibited insulin-stimulated glycogen synthesis inboth soleus and EDL muscle preparations. Rat CGRP-1 was a potent 
stimulator f glycogenolysis only in muscles composed of type II fibres, which depend on high rates of glycogenolysis 
to produce high power outputs. These results may provide the basis for understanding how CGRP regulate glyeogenolysis 
in type II fibres in vivo. 
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1. INTRODUCTION 
Skeletal muscle is composed of several fibre 
types. Slow twitch (type I) fibres have a low maxi- 
mum velocity of shortening (Vm~x) [1] and are 
specialised for protracted use at relatively low velo- 
cities [2]. Fast twitch or type II fibres, which are 
subclassified as type I IA and liB, have a high Vmax 
[1] and are necessary for maximal rates of locomo- 
tion which require large power outputs [3]. Type II 
fibres have the capacity for high rates of ATP 
production. This is achieved by increased rates of 
release of glucosyl units from muscle glycogen (gly- 
cogenolysis) and subsequent glycolytic conversion 
to lactate. Glycogenolytic and glycolytic potential, 
as measured by maximal enzyme activities, are 
2-6-fold higher in type II fibres as compared with 
type I fibres [4,5]. Adrenaline stimulates glyco- 
genolysis in skeletal muscle via/5'-adrenoceptors. 
Surprisingly, responsiveness of muscle glycogeno- 
lysis to fl-adrenergic stimulation is greater in type I 
than in type II fibres [6-8]. Noradrenaline has little 
effect on glycogen metabolism in skeletal muscle 
[9]. The neuropeptide calcitonin gene-related pep- 
tide (CGRP) has 46°70 primary amino acid se- 
quence identity with the pancreatic peptide amylin 
[12]. Both peptides inhibit basal and insulin- 
stimulated glycogen synthesis in incubated stripped 
soleus muscle preparations [10,13]. Soleus is large- 
ly populated with type I fibres. There is evidence 
for localisation of CGRP in both sensory nerves 
[14] and in the motor end plate axon terminal [15] 
in skeletal muscle. In view of the potential neuroen- 
docrine role of this peptide we studied its effects in 
muscles largely composed of type II fibres (i.e. ex- 
tensor digitorum longus, EDL, and epitrochlearis). 
Also, since the EDL muscles were isolated from 
young rodents the effect of CGRP-1 on intact 
soleus muscle preparations was also measured. 
2. MATERIALS AND METHODS 
Correspondence address: B. Leighton, Department of Bio- 
chemistry, University of Oxford, South Parks Road, Oxford 
OX1 3QU, England 
2.1. Materials 
Male Wistar ats were obtained from Harlan Olac (Bicester, 
England) and were maintained in the Department's animal 
house. Chemicals and enzymes were obtained from sources 
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given in [7,13] except for the cAMP radioimmunoassay kit 
which was purchased from Amersham. 
2.2. Incubation studies and metabolite assays 
Intact soleus and EDL muscles were prepared from 12-h 
fasted rats as described previously [16]. The tendons of the 
muscles were ligated before attachment to stainless steel clips. 
Muscle strips were pre-incubated in Erlenmeyer flasks contain- 
ing 3.5 ml Krebs-Ringer bicarbonate buffer plus 7 mM N-2-hy- 
droxyethylpiperazine-N'-2-ethanesulphonic acid, pH 7.4, 5.5 
mM glucose, 5mM pyruvate 5, 1.5°70 (w/v) de-fatted bovine 
serum albumin. Flasks were sealed and aerated continuously 
with O2:CO2 (19:1, v/v). After pre-incubation f muscles inthis 
medium for 30 min, at 37°C in an oscillating water bath, the 
muscle strips were transferred tosimilar vials containing iden- 
tical medium (except yruvate was omitted) with added [U-~4C] - 
glucose (0.5/zCi/ml) and insulin (100/~U/ml). The flasks were 
sealed, re-gassed for the initial 15 rain period in a 1 h- 
incubation. At the end of the incubation period, muscles were 
blotted and rapidly frozen in liquid nitrogen. The concentration 
of lactate in the incubation medium and plasma was determined 
spectrophotometrically [17] or radiochemically [18] and 
[U-~4C]glucose incorporated into glycogen (glycogen synthesis) 
was measured [19]. 
Rates of glycogen synthesis were measured in terms of/zmol 
of glucosyl units'h-l-g ~. One glucosyl unit indicates one 
glucose moiety incorporated into glycogen. For measurement of 
cAMP levels, muscles were powdered under liquid N2 before ad- 
dition of perchloric acid (6070) and the mixture was reground. 
The concentration f cAMP was measured in neutralised x- 
tracts with a radioimmunoassay kit. 
3. RESULTS AND DISCUSSION 
The effects of various concentrations of rat 
CGRP-1 on the rates of lactate formation and gly- 
cogen synthesis were studied in both the intact 
soleus and EDL muscle preparations in vitro and 
the results are shown on fig. 1. In both intact EDL 
and soleus muscles CGRP-1 inhibited the insulin- 
stimulated rates of glycogen synthesis in a concen- 
tration-dependent manner: the CGRP-1 ECs0 
values (i.e. the concentration f hormone necessary 
for a half-maximal response) for glycogen syn- 
thesis were about 0.58 nM and 0.56 nM, respective- 
ly. Only the highest concentration (100 nM) of 
CGRP-1 significantly stimulated the rate of lactate 
formation in the intact soleus muscle. In marked 
contrast, CGRP-1, in the presence of insulin, 
stimulated the rate of lactate formation in a 
concentration-dependent fashion in the isolated, 
intact EDL muscle preparation. The calculated 
ECso value for stimulation of lactate formation 
was 1.35 nM (if 100 nM CGRP-1 gave the maximal 
response). Indeed, if the rate of lactate formation 
is increased at a higher concentration of CGRP-1 
then the EC 5o value from the present results will be 
an underestimate. CGRP-1 also stimulated lactate 
formation in isolated incubated epitrochlearis mus- 
cle, which is composed of type II fibres (table 1). 
In isolated, incubated muscle preparations lac- 
tate is formed by glycolytic onversion of glucose 
molecules that are taken up from the incubation 
medium (measured as radiochemical lactate forma- 
tion) or from muscle glycogen [19,20]. In theory, 
lactate concentration determined spectrophotome- 
trically is a measure of the rate of conversion of 
glucose derived from both sources. In EDL muscle 
CGRP-1 stimulated only the rates of spectrophoto- 
metric lactate formation (fig.l), but not rates of 
radiochemical lactate formation (fig. 1) or glucose 
oxidation (results not given); this suggests that 
CGRP-1 stimulated glycogen breakdown but did 
not affect glucose uptake. Furthermore, these 
results suggest that the sensitivity of glycogenolysis 
to CGRP-1 is markedly decreased in type I fibres in 
comparison with type II fibres. Phosphorylation f 
glycogen phosphorylase, which results in rapid 
breakdown of glycogen, is caused, at least in part, 
by fl-adrenergic agents via a mechanism dependent 
on cAMP [22,23]. A concentration of CGRP-1 (10 
nM), which maximally decreased the rates of 
glycogen synthesis in both soleus and EDL prepa- 
rations, increased the levels of cAMP only in EDL 
muscles (table 2). This would suggest that the 
mechanism of inhibition of glycogen synthesis by 
CGRP-1 does not involve cAMP alone. Further- 
more, CGRP-1 (1 nM) had no effects on the rates 
of radiochemical lactate formation in type II fibres 
incubated in the presence of various concentrations 
of insulin, but the rates of spectrophotometric lac- 
tate formation were significantly increased at all 
concentrations of insulin (see fig.2). 
The soleus muscle of the rat has a post-natal 
period of maturing, and most of the fast-twitch 
changes to slow twitch fibres occur over the first 
few months [24,25]. The intact soleus muscle 
preparation used in the present study is expected to 
be populated with 80°7o type I fibres, the rest being 
type I IA [24,25]. EDL and epitrochlearis muscle 
both contain > 9007o type II fibres (about 50o70 and 
70°70 type IIB fibres, respectively [26,27]). The 
chief difference between soleus and other muscles 
is the presence of type IIB fibres. Our results sug- 
gest that CGRP-1 may specifically stimulate 
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Fig.1. Concentration-dependent effects of rat calcitonin gene-related peptide-1 (CGRP-1) (Sigma) on insulin-stimulated (uU. m1-1) 
rates of (a) spectrophotometric la tate formation and (b) glycogen synthesis in isolated incubated intact soleus (©) and extensor 
digitorum longus (EDL) (e) muscle preparations. The rates of radiochemical l ctate formation in incubated EDL muscle preparations 
are also shown in (A). The values are presented as means _+ standard errors of the means of at least four separate xperiments. 
Statistically significant changes from muscles incubated in the absence of CGRP-I are indicated by * (Student's t-test; P<0.05). 
Statistically significant changes between soleus and EDL muscles at any given concentration f CGRP-1 are indicated by + (/)<0.05). 
g lycogenolys is ,  and hence lactate fo rmat ion ,  in 
type I IB  f ibres in certa in condi t ions ,  for  example ,  
dur ing  high intensity exercise. Quant i tat ive ly ,  the 
ch ie f  site o f  lactate product ion  is skeletal  muscle  
[28]. Lactate  is c leared f rom the b loodst ream main-  
ly by  the l iver [29,30] by convers ion ,  via 
g luconeogenes is ,  to glucose. In type II (non 
Table 1 
The effects of rat calcitonin gene-related peptide-1 (CGRP- 1) 
on insuling-stimulated rates of lactate formation and glycogen 
synthesis in the incubated epitrochlearis muscle of the rat 
Treatment Rates ~mol/h per g wet wt) 
Lactate formation Glycogen synthesis 
Control 13.93 + 0.62 3.95 _+ 0.38 
CGRP (10 nM) 17.89 ± 1.29" 2.55 ± 0.23* 
All results present means _+ SE for at least three replicate 
experiments. Significant differences between control and 
treated muscles (non-paired Student's t-test) are indicated by 
asterisks, P<0.05. Insulin was present in the incubation 
medium at a concentration of 100/zU/ml 
insu l in -dependent)  d iabetes there is a greater  f lux 
th rough the g luconeogen ic  pathway in both  the 
post -p rand ia l  and post -absorpt ive  states [31-33]. 
Table 2 
Effects of rat calcitonin gene-related peptide-I (CGRP) on the 
rates of lactate formation and cyclic AMP content in incubated 
intact soleus and extensor digitorum longus (EDL) muscle 
preparations of the rat 
Rates or content ~mol. 10 min -~ .g-1 
or/zmol, g-l) 
Lactate formation cAMP content 
Soleus 
Control 1.5 _+ 0.2 (12) 212 ± 24 (11) 
CGRP 1.9 _+ 0.1 (12) 255 _+ 44 (10) 
EDL 
Control 1.5 _+ 0.2 (11) 141 + 18 (11) 
CGRP 2.7 × 0.2 (12)* 292 _+ 7 (10)* 
All results presented as means ± SE for the number of 
observations given in parentheses. Statistically significant 
differences (non-paired Student's t-test) between control and 
treated muscles are indicated by asterisks, P< 0.001 
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Fig.2. Effects of insulin on the rates of spectrophotometric (©,e) and radiochemical (zx, A) lactate formation i  incubated intact exten- 
sor digitorum longus muscle preparations of the rat incubated in the presence (e, A) and absence ((3, A) of rat calcitonin gene-related 
peptide-1. Results are presented as means + standard errors of the means of at least four individual experiments. Statistically significant 
differences between (non-paired Student's t-test) control (O,zx) and muscles treated with rat CGRP-1 (e,A) are indicated by * 
(P<0.05). 
This would be expected to decrease the concentra- 
t ion of  lactate in the b lood.  Paradoxica l ly  high 
b lood lactate concentrat ions are found in type II 
diabetic subjects [34-36]. This may be explained by 
higher rates of  lactate format ion from skeletal 
muscle which may be caused by higher levels of  
CGRP and/or  amylin [13] and the much higher 
content of  type l iB  fibres [37] in insulin resistant 
subjects. Therefore,  the results of  the present study 
are consistent with the hypothesis that an abnor-  
mal i ty  in CGRP and/or  amyl in homeostasis 
underl ies the pathogenesis of type II  diabetes [13]. 
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Evidence for a factor promoting the conversion of VWF from low 
and intermediate to high molecular mass polymers on the platelet 
membrane 
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On the membrane surface of resting platelets exists a factor capable of promoting the conversion of plasma von Wille- 
brand factor from low and intermediate molecular mass to high molecular mass polymers. The process is accompanied 
by a parallel increase in the von Willebrand factor activity. This could be a regulatory system for the molecular mass 
distribution of von Willebrand factor during its lifetime in plasma. Glycoprotein Ib of the platelet membrane appears 
not to be involved in the process. 
Hemostasis; Platelet; Von Willebrand factor; Ristocetin 
1. INTRODUCTION 
The von Willebrand disease is an autosomic 
coagulation disorder due to a quali- and/or quan- 
titative deficiency of the von Willebrand factor 
(vWF), a large glycoprotein produced by the en- 
dothelial cells and megacaryocytes [1-3]. In 
plasma, vWF circulates as a heterogeneous mixture 
of disulfide-bridged polymers ranging from dimers 
(Mr 25X104) to multimers (Mr>2× 107) and its 
role is to promote the initial step in hemostatic plug 
formation [4] by interacting with the suben- 
dothelial structures (collagen) of injured vessel and 
with the glycoprotein IIb-IIIa of activated platelets 
[5,6]. In the presence of the antibiotic ristocetin, 
vWF is capable of interacting with resting platelets 
too: in this case the platelet membrane glycopro- 
tein Ib is responsible for the interaction with the 
ristocetin-vWF complex [7-11] by which platelets 
are activated and aggregate. Glycoprotein Ib re- 
tains the capability to interact with the ristocetin- 
vWF complex also when platelets are metabolically 
Correspondence address: A. Ferri, Istituto di Chimica 
Biologica, UniversitA degli Studi, Via L. Borsari 46, 1-44100 
Ferrara, Italy 
inactive such as after treatment with formaldehyde 
[12,13]; in this case agglutination of FFP occurs. 
Both the physiological interaction of vWF with 
activated platelets, and the non-physiological in- 
teraction of the ristocetin-vWF complex with 
resting or inactivated platelets, strongly depend on 
the molecular mass of the polymers, the highest ac- 
tivity being shown by the largest molecules. 
A lot of information exists indicating that the 
vWF molecules produced by the endothelial cells 
are stored into the Weibel-Palade bodies as a mix- 
ture containing all the polymeric forms, but it is 
not known, to date, whether this is the only way by 
which the HMW polymers are produced, or 
whether polymerization may also occur after the 
secretion of glycoprotein into blood [14-16]. The 
problem becomes more puzzling because of the re- 
cent observation [17] that the proteolytic leavage 
of the precursor (pro-vWF) seems not to be essen- 
tial for the multimers formation. 
In the present paper we show that on the resting 
platelet membrane surface there is a factor capable 
of promoting the conversion of vWF from low and 
intermediate molecular mass to high molecular 
mass polymers with a consequent increase in the 
vWF activity. 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
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2. MATERIALS AND METHODS 
2.1 Materials 
All reagents were analytical grade. Human platelet poor 
plasma (PPP) was prepared by double centrifugation (2000 × g; 
15 rain) of citrate (0.38°70) added to fresh blood samples from 
volunteers. Platelet rich plasma (PRP) was obtained by double 
centrifugation of citrate added to blood (200xg; 8 min). 
Washed platelets (WP) were prepared immediately before use by 
centrifugation of PRP (3000xg; 15 min) followed by three 
washing cycles of the pellet with 10 mM Tris, 1 mM EDTA, pH 
7.5, buffer (Tris-EDTA buffer): from 40 ml of fresh blood we 
usually obtained 10 ml of washed platelets ( -4x  103 WP//~I). 
Formaldehyde-fixed platelets (FFP) were prepared by one hour 
preincubation f PRP suspensions (10 ml) at 37°C, followed by 
centrifugation (2500 × g; 15 min) and resuspension f the pellet 
in 10 ml of Tris-EDTA buffer containing 2070 formaldehyde; 
after 48 h incubation at 4°C the suspension was centrifuged 
(2500 x g; 15 min) and the pellet was resuspended in Tris-EDTA 
buffer giving 3 x 105 FFP/#I (10-12 ml) and stored at 4°C. In- 
cubations of PPP samples with FFP or WP were performed by 
centrifuging (3000 x g; 15 rain) the desired amount of platelets 
from the storage buffer and gently resuspending the pellet in the 
required volume of plasma to be treated. 
The experiments requiring WP were preceded by a control on 
the integrity of platelets by suspending them (3 × l0 s WP/ml) in 
200 ttl of PPP in the aggregometer vessel and following the ag- 
gregation process induced by 2 ttM ADP. Parallel to these x- 
periments, aggregometric controls were routinely performed in
order to check whether incidental activation of WP occurred 
during incubations. 
2.2. vWF activity in plasma 
200 #1 of FFP suspension (3 x 105 FFP//d), supplemented with 
1 mg/ml ristocetin, were preincubated 3 min at 37°C into the ag- 
gregometer vessel under stirring, after which 50 td of the PPP to 
be tested were added; the aggregometer (Menarini) recorded the 
increase in transmittance, due to the agglutination of platelets, 
vs time. The slope of the initial agglutination time course was 
proportional to the activity of the vWF in the sample. We 
assumed 10007o activity to be that obtained for a PPP sample 
from a pool of blood samples from voluntary donors under the 
indicated test conditions. 
2.3 Agarose gel electrophoresis, transblotting, staining 
Gel electrophoresis was performed substantially as in [18] 
with some modifications. Gels, 1 mm thick, were 10x 10 cm 
size, the stacking and the running parts were 0.75% and 1.7507o 
agarose and were 2.5 cm and 7.5 cm in length, respectively; sam- 
ple wells (2 x 0.2 cm) were cut in the stacking el at 1 cm from 
the interface. Plasma to be investigated was diluted 5-fold with 
Tris-EDTA buffer adjusted to pH 8.0 and containing 2°70 SDS, 
8 M urea and 0.01% bromophenol blue as tracking dye. After 
20 min incubation at 60°C, 20 #1 samples were applied to each 
well and electrophoresis tarted at 20 mA constant current. 
After the samples had moved out of the wells, these were filled 
with stacking el suspension and the current was decreased to4 
mA. Electrophoresis was stopped when the dye reached the 
anode end of the gel (usually 14 h). After the run the gel was 
transblotted onto a nitrocellulose sheet (Bio-Rad, 10x 10 cm, 
0.22/~m) by a standard transblot chamber (Bio-Rad) and follow- 
ing the recommended procedure (24 h run; 200 mA constant 
current; 4°C temperature; running buffer, 15.6 mM Tris, 120 
mM glycine, pH 8.3, containing 0.05070 SDS, 20% methanol). 
The nitrocellulose heet was treated (30 min) with fixing buffer 
(2-propanol/acetic acid/water, 25:10:65), washed three times 
with Tris-NaCl buffer (50 mM Tris, 150 mM NaCI, pH 7.5), 
saturated by incubation (30 min) in Tris-NaC1 buffer containing 
1 ~70 bovine serum albumin and washed three times with Tris- 
NaC1 buffer containing 1°70 Triton X-100. Staining was ob- 
tained by a 4 h incubation of the nitrocellulose heet with perox- 
idase-conjugated anti-human vWF rabbit antiserum (DAKO) 
diluted 1:125 with Tris-NaC1 buffer containing 1°70 Triton 
X-100, followed by four washing cycles with the same buffer 
and four washing cycles with Tris-NaC1 buffer. The last washing 
bath was supplemented, in the dark, with 0.5 mg/ml 
4-chloro-l-naphthol (predissolved in methanol) and 5 mM 
hydrogen peroxide. The incubation was stopped after 20 rain by 
repeated washings with distilled water. After air drying, the 
nitrocellulose heet was photographed. 
3. RESULTS AND DISCUSSION 
A typical PPP from healthy donors shows the 
molecular mass distribution of vWF polymers 
represented in fig. 1 (lane 1), the activity (as defined 
in section 2.2) of which was taken as 10001o. In the 
presence of ristocetin and FFP, a ristocetin-vWF 
complex was formed capable of interacting with 
the membrane glycoprotein Ib of FFP [12,13] by 
which agglutination occurred and, consequently, 
the removal of vWF bound to platelets from the 
medium was possible by centrifugation. As shown 
in lane 2, by an agglutination-centrifugation treat- 
ment, the high molecular mass vWF polymers 
(HMW-vWF) were removed from plasma with a 
drop of activity to 25°70 with respect o sample 1. 
The intermediate molecular mass polymers (IMW- 
vWF) were removed from plasma by a second iden- 
tical treatment by which only the low molecular 
mass polymers (LMW-vWF, i.e. dimers and 
tetramers) remained in the medium with an activity 
near zero (lane 3). 
A PPP sample (fig.2, lane 1), subjected to an ag- 
glutination-centrifugation treatment toremove the 
HMW-vWF polymers, was incubated with WP and 
subsequently centrifuged. In the supernatant ob- 
tained after an hour of incubation (lane 3), the 
trace corresponding to the highest polymer of lane 
2 completely disappeared and, after two hours of 
incubation, a sharp decrease in the intensity of all 
traces was observed. This result is interpreted as a 
consequence of the concurrent effects of WP and 
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